Neonatal screening for congenital hypothyroidism: results and perspectives
Related Experiment Videos
1Department of Pediatrics, University Hospital Saint-Pierre, Brussels, Belgium. fdelange@ulb.ac.be
Insights
Early screening for congenital hypothyroidism in newborns is crucial for preventing intellectual disability. Prompt treatment with thyroxine within 14 days ensures normal development, even in cases of fetal hypothyroidism.
Area of Science:
- Pediatrics
- Endocrinology
- Public Health
Background:
- Congenital hypothyroidism affects 1 in 4,000 newborns.
- Untreated, it leads to irreversible brain damage and mental retardation.
- Neonatal screening is vital for early detection and intervention.
Purpose of the Study:
- To highlight the importance of systematic newborn screening for congenital hypothyroidism.
- To discuss diagnostic and therapeutic strategies.
- To review outcomes and prognosis for affected infants.
Main Methods:
- Universal screening using primary thyroid-stimulating hormone (TSH) tests.
- Early initiation of thyroxine therapy within 14 days of birth.
- Monitoring of iodine deficiency correction at a population level.
Main Results:
- Early thyroxine treatment (10 mcg/kg/day) effectively prevents brain damage.
- Maternal thyroxine provides fetal protection.
- Neonatal screening monitors iodine deficiency impact and correction.
Conclusions:
- Systematic congenital hypothyroidism screening is a major advancement in preventing mental retardation.
- Timely diagnosis and treatment are essential for optimal neurodevelopmental outcomes.
- Neonatal thyroid screening serves as a valuable public health tool for iodine status assessment.
Abstract:
Systematic screening for congenital hypothyroidism in the neonate constitutes a major progress in the prevention of mental retardation, as the condition occurs in 1/4,000 newborns and necessarily results in brain damage if not properly detected and treated during the first days of life. Screening and diagnostic and therapeutic procedures are discussed, as well as outcome and prognosis of the affected infants. Primary thyroid-stimulating hormone screening is almost universally recommended. Early therapy (within 14 days) with appropriate doses of thyroxine (about 10 micrograms/kg/day) will prevent any brain damage even in case of evidence of fetal hypothyroidism, as thyroxine of maternal origin will reach the fetus and largely protect him. Neonatal thyroid screening is also a particularly sensitive monitoring tool in the evaluation of the effects and of the correction of iodine deficiency at the population level.
Related Concept Videos
01:23Hypothyroidism II: Pathophysiology
01:25Hyperthyroidism I: Introduction
01:27Hyperthyroidism II: Pathophysiology